- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Charles Saunders, MD: Biosimilars in Specialty Pharmacy
Charles Saunders, MD, CEO of Integra Connect, discusses the promise of biosimilars in specialty pharmacy.
Transcript:
How are you seeing biosimilars impact the world of specialty pharmacy?
I think that the promise of biosimilars to bring down the cost of drugs is certainly out there based on the experience that we’ve had with generics. I’m not sure that we’re really seeing the impact as great, though, because the prices of the biosimilars are not that much lower than the other drugs—so, maybe 25% to 35% reduction.
I think also, in some cases, I think providers are not—they might be a little bit more reluctant to switch in the case of a therapeutic agent until there’s more clinical evidence of efficacy. And that’s not the case necessarily with supportive therapy, where it’s much easier to make that switch.
So, impact there, promise still there, I think there could be some pricing advantages to the providers that have a “buy and bill” program or they pay a little bit lower price for the acquisition of the drug. Then, if it’s reimbursed at [average sales prices, ASP] plus 6%, they just have a lower cost basis on a drug, so there’s some economic advantages too.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
